DRAFT landscape of COVID-19 candidate vaccines – 4 JAN 2022
137 candidate vaccines in clinical evaluation
| ID | Vaccine platform acronym | Vaccine platform description | Type of candidate vaccine | Route of administration | Developers | Phase | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | |
| 1 | IV | Inactivated virus | CoronaVac; SARS-CoV-2 vaccine (inactivated) | IM | Sinovac Research and Development Co., Ltd | Phase 4 | NCT04383574 | NCT04754698** | NCT04456595 | NCT04756830 | |||
| Study Report | Study Protocol | NCT04747821 | |||||||||||
| NCT04352608 | NCT04508075 | NCT04775069 | |||||||||||
| NCT04551547 | NCT04582344 | ||||||||||||
| Study Report | NCT04617483 | ||||||||||||
| Study Report | NCT04651790 | ||||||||||||
| 2 | IV | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | IM | Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products | Phase 3 | |||||||
| NCT04510207 * | |||||||||||||
| Interim Report | NCT04612972 | ||||||||||||
| 3 | IV | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | IM | Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products | Phase 3 | ChiCTR2000032459 | NCT04560881 | |||||
| Study Report | NCT04510207* | ||||||||||||
| 4 | VVnr | Viral vector (Non-replicating) | ChAdOx1-S - (AZD1222) (Covishield) | IM | AstraZeneca + University of Oxford | Phase 4 | PACTR202005681895696 | PACTR202006922165132 | NCT04686773 | NCT04400838 | ISRCTN89951424 | NCT04760132 | |
| 2020-001072-15 | Study Report | NCT04516746 | NCT04775069 | ||||||||||
| Interim Report | ISRCTN69254139 | Study Report | NCT04540393 | ||||||||||
| NCT04568031 | Study Report | NCT04536051 | |||||||||||
| Study Report | Study Report | EUCTR2020-005226-28-DE | |||||||||||
| NCT04444674 | Study Report | ||||||||||||
| NCT04324606 | CTRI/2020/08/027170 | Study Report | |||||||||||
| Study Report | ISRCTN69254139 | ||||||||||||
| Study Report | |||||||||||||
| Study Report | |||||||||||||
| NCT04684446 | |||||||||||||
| ISRCTN15638344 | |||||||||||||
| NCT04760730 | |||||||||||||
| 5 | VVnr | Viral vector (Non-replicating) | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) | IM | CanSino Biological Inc./Beijing Institute of Biotechnology | Phase 3 | NCT04526990 | ||||||
| NCT04313127 | NCT04398147 | NCT04566770 | NCT04540419 | ||||||||||
| NCT04568811 | NCT04341389 | ||||||||||||
| NCT04552366 | |||||||||||||
| Study Report | Study Report | ||||||||||||
| 6 | VVnr | Viral vector (Non-replicating) | Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) | IM | Gamaleya Research Institute ; Health Ministry of the Russian Federation |
Phase 3 | NCT04436471 | NCT04530396 | |||||
| Study Report | |||||||||||||
| NCT04437875 | NCT04564716 | ||||||||||||
| NCT04713488 | NCT04587219 | NCT04642339 | |||||||||||
| Study Report | NCT04640233 | NCT04656613 | |||||||||||
| NCT04760730 | NCT04741061 | ||||||||||||
| 7 | VVnr | Viral vector (Non-replicating) | Ad26.COV2.S | IM | Janssen Pharmaceutical | Phase 3 | NCT04509947 | NCT04436276 | EUCTR2020-002584-63-DE | NCT04505722 | |||
| Study Report | NCT04535453 | Study Report | |||||||||||
| Study Report | NCT04765384 | NCT04614948 | |||||||||||
| 8 | PS | Protein subunit | SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) | IM | Novavax | Phase 3 | NCT04368988 |
NCT04533399 | NCT04611802 | ||||
| Study Report | EUCTR2020-004123-16-GB | ||||||||||||
| Study Report | NCT04583995 | ||||||||||||
| 9 | RNA | RNA based vaccine | mRNA -1273 | IM | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | NCT04283461 | NCT04677660 | NCT04405076 | NCT04649151 | NCT04470427 | NCT04760132 | |
| Interim Report | NCT04712110 | Study Report | Study Report | ||||||||||
| Study Report | NCT04761822 | ||||||||||||
| 10 | RNA | RNA based vaccine | BNT162 (3 LNP-mRNAs ) | IM | Pfizer/BioNTech + Fosun Pharma | Phase 4 | NCT04523571 | 2020-001038-36 | NCT04649021 | NCT04754594 | NCT04368728 | NCT04760132 | |
| Study Report | NCT04588480 | NCT04761822 | Study Report | EUCTR2021-000412-28-BE | |||||||||
| NCT04380701 | Study Report | EUCTR2021-000412-28-BE | |||||||||||
| Study Report | NCT04713553 | NCT04780659 | |||||||||||
| NCT04537949 | NCT04775069 | ||||||||||||
| EUCTR2020-003267-26-DE | |||||||||||||
| Study Report | |||||||||||||
| 11 | PS | Protein subunit | Recombinant SARS-CoV-2 vaccine (CHO Cell) | IM | Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences | Phase 3 | NCT04445194 | NCT04550351 | NCT04466085 | ||||
| ChiCTR2000035691 | Study Report | NCT04646590 | |||||||||||
| NCT04636333 | |||||||||||||
| 12 | RNA | RNA based vaccine | CVnCoV Vaccine | IM | CureVac AG | Phase 3 | NCT04449276 | NCT04515147 | NCT04652102 | NCT04674189 | |||
| PER-054-20 | |||||||||||||
| 13 | IV | Inactivated virus | SARS-CoV-2 vaccine (vero cells) | IM | Institute of Medical Biology + Chinese Academy of Medical Sciences | Phase 3 | NCT04470609 | NCT04659239 | |||||
| NCT04412538 | |||||||||||||
| Study Report | |||||||||||||
| 14 | IV | Inactivated virus | QazCovid-in® - COVID-19 inactivated vaccine | IM | Research Institute for Biological Safety Problems, Rep of Kazakhstan | Phase 3 | NCT04530357 | NCT04691908 | |||||
| 15 | DNA | DNA based vaccine | INO-4800+electroporation | ID | Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd | Phase 2/3 | NCT04336410 | NCT04447781 | NCT04642638 | ||||
| Study Report | |||||||||||||
| ChiCTR2000038152 | |||||||||||||
| 16 | DNA | DNA based vaccine | AG0301-COVID19 | IM | AnGes + Takara Bio + Osaka University | Phase 2/3 | NCT04463472 | NCT04655625 | |||||
| NCT04527081 | |||||||||||||
| jRCT2051200085 | |||||||||||||
| 17 | DNA | DNA based vaccine | nCov vaccine | ID | Zydus Cadila | Phase 3 | CTRI/2020/07/026352 | CTRI/2020/07/026352 | |||||
| 18 | DNA | DNA based vaccine | GX-19 | IM | Genexine Consortium | Phase 1/2 | NCT04445389 | ||||||
| NCT04715997 | |||||||||||||
| 19 | IV | Inactivated virus | Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) | IM | Bharat Biotech International Limited | Phase 3 | NCT04471519 | NCT04641481; CTRI/2020/11/028976 | |||||
| Interim Study Report | |||||||||||||
| Study Report | |||||||||||||
| Study Report | |||||||||||||
| CTRI/2020/07/026300 | |||||||||||||
| CTRI/2020/09/027674 | |||||||||||||
| 20 | PS | Protein subunit | KBP-COVID-19 (RBD-based) | IM | Kentucky Bioprocessing Inc. | Phase 1/2 | NCT04473690 | ||||||
| 21 | PS | Protein subunit | VAT00002: SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (S protein (baculovirus production) | IM | Sanofi Pasteur + GSK | Phase 3 | NCT04537208 | NCT04762680 | PACTR202011523101903** | ||||
| 22 | RNA | RNA based vaccine | ARCT-021 | IM | Arcturus Therapeutics | Phase 2 | NCT04480957 | NCT04668339 | |||||
| NCT04728347 | |||||||||||||
| 23 | VLP | Virus like particle | RBD SARS-CoV-2 HBsAg VLP vaccine | IM | Serum Institute of India + Accelagen Pty + SpyBiotech | Phase 1/2 | ACTRN12620000817943 | ||||||
| ACTRN12620001308987 | |||||||||||||
| 24 | IV | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | IM | Beijing Minhai Biotechnology Co | Phase 2 | NCT04758273 | NCT04756323 | |||||
| 25 | VVnr | Viral vector (Non-replicating) | GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S) | IM | ReiThera + Leukocare + Univercells | Phase 2/3 | NCT04528641 | EUCTR2020-005915-39-IT | |||||
| 26 | VVnr | Viral vector (Non-replicating) | VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform | Oral | Vaxart | Phase 1 | NCT04563702 | ||||||
| 27 | VVnr | Viral vector (Non-replicating) | MVA-SARS-2-S | IM | University of Munich (Ludwig-Maximilians) | Phase 1 | NCT04569383 | ||||||
| 28 | PS | Protein subunit | SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Native like Trimeric subunit Spike Protein vaccine) | IM | Clover Biopharmaceuticals Inc./GSK/Dynavax | Phase 2/3 | NCT04405908 | NCT04672395 | |||||
| Study Report | |||||||||||||
| Report | |||||||||||||
| 29 | PS | Protein subunit | COVAX-19® Recombinant spike protein + adjuvant | IM | Vaxine Pty Ltd. | Phase 1 | NCT04453852 | ||||||
| Protein subunit | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine | IM | CSL Ltd. + Seqirus + University of Queensland | Phase 1 | Development has been suspended and the candidate vaccine has been removed from the landscape summary analysis | ||||||||
| 30 | PS | Protein subunit | MVC-COV1901 (S-2P protein + CpG 1018) | IM | Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | NCT04487210 | NCT04695652 | |||||
| 31 | PS | Protein subunit | FINLAY-FR1 anti-SARS-CoV-2 Vaccine (RBD + adjuvant) | IM | Instituto Finlay de Vacunas | Phase 1/2 | RPCEC00000338 | RPCEC00000332 | |||||
| 32 | PS | Protein subunit | FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant) | IM | Instituto Finlay de Vacunas | Phase 3 | RPCEC00000340 | RPCEC00000347 | RPCEC00000354 | ||||
| 33 | PS | Protein subunit | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | IM | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 3 | NCT04527575 | NCT04780035 | |||||
| 34 | PS | Protein subunit | RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell) | IM | West China Hospital + Sichuan University | Phase 2 | |||||||
| NCT04530656 | NCT04640402 | ||||||||||||
| NCT04718467 | |||||||||||||
| 35 | PS | Protein subunit | IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) | SC | University Hospital Tuebingen | Phase 1 | NCT04546841 | ||||||
| 36 | PS | Protein subunit | UB-612 (Multitope peptide based S1-RBD-protein based vaccine) | IM | COVAXX + United Biomedical Inc | Phase 2/3 | NCT04545749 | NCT04773067 | NCT04683224 | ||||
| Viral vector (Replicating) | V591-001 - Measles-vector based (TMV-o38) | IM | Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + University of Pittsburgh | Phase 1/2 | NCT04497298 | CT04498247 | Development has been suspended and the candidate vaccines has been removed from the landscape summary analysis | ||||||
| NCT04569786 | |||||||||||||
| 37 | VVr | Viral vector (Replicating) | DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) | IN | University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy | Phase 2 | ChiCTR2000039715 | ||||||
| 38 | RNA | RNA based vaccine | LNP-nCoVsaRNA | IM | Imperial College London | Phase 1 | ISRCTN17072692 | ||||||
| 39 | RNA | RNA based vaccine | SARS-CoV-2 mRNA vaccine (ARCoV) | IM | Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences | Phase 1 | |||||||
| ChiCTR2000039212 | |||||||||||||
| 40 | VLP | Virus like particle | Coronavirus-Like Particle COVID-19 (CoVLP) | IM | Medicago Inc. | Phase 2/3 | NCT04662697 | NCT04636697 | |||||
| Study Report | |||||||||||||
| 41 | VVr + APC | Viral vector (Replicating) + APC | Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs). | SC | Shenzhen Geno-Immune Medical Institute | Phase 1 | NCT04299724 | ||||||
| 42 | VVnr + APC | Viral vector (Non-replicating) + APC | LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens. | SC & IV | Shenzhen Geno-Immune Medical Institute | Phase 1/2 | NCT04276896 | ||||||
| 43 | PS | Protein subunit | AdimrSC-2f (recombinant RBD +/- Aluminium) | ND | Adimmune Corporation | Phase 1 | NCT04522089 | ||||||
| 44 | DNA | DNA based vaccine | Covigenix VAX-001 - DNA vaccines + proteo-lipid vehicle (PLV) formulation | IM | Entos Pharmaceuticals Inc. | Phase 1 | NCT04591184 | ||||||
| 45 | DNA | DNA based vaccine | CORVax - Spike (S) Protein Plasmid DNA Vaccine | ID | Providence Health & Services | Phase 1 | NCT04627675 | ||||||
| 46 | RNA | RNA based vaccine | ChulaCov19 mRNA vaccine | IM | Chulalongkorn University | Phase 1 | NCT04566276 | ||||||
| 47 | DNA | DNA based vaccine | bacTRL-Spike oral DNA vaccine | Oral | Symvivo Corporation | Phase 1 | NCT04334980 | ||||||
| 48 | VVnr | Viral vector (Non-replicating) | Human Adenovirus Type 5: hAd5 S+N vaccine (S-Fusion + N-ETSD). E2b- Deleted Adeno. | SC or Oral | ImmunityBio, Inc. & NantKwest, Inc. | Phase 1 | NCT04591717 | ||||||
| NCT04710303 | |||||||||||||
| NCT04732468 | |||||||||||||
| 49 | VVnr | Viral vector (Non-replicating) | COH04S1 (MVA-SARS-2-S) - Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2 | IM | City of Hope Medical Center + National Cancer Institute | Phase 1 | NCT04639466 | ||||||
| Pre-clinical result | |||||||||||||
| 50 | VVr | Viral vector (Replicating) | rVSV-SARS-CoV-2-S Vaccine | IM | Israel Institute for Biological Research | Phase 1/2 | NCT04608305 | ||||||
| 51 | VVr + APC | Viral vector (Replicating) + APC | Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF | IM | Aivita Biomedical, Inc. National Institute of Health Research and Development, Ministry of Health Republic of Indonesia |
Phase 1/2 | NCT04690387 | NCT04386252 | |||||
| NCT04685603 | |||||||||||||
| 52 | LAV | Live attenuated virus | COVI-VAC | IN | Codagenix/Serum Institute of India | Phase 1 | NCT04619628 | ||||||
| 53 | PS | Protein subunit | CIGB-669 (RBD+AgnHB) | IN | Center for Genetic Engineering and Biotechnology (CIGB) | Phase 1/2 | RPCEC00000345 | ||||||
| 54 | PS | Protein subunit | CIGB-66 (RBD+aluminium hydroxide) | IM | Center for Genetic Engineering and Biotechnology (CIGB) | Phase 1/2 | RPCEC00000346 | ||||||
| 55 | IV | Inactivated Virus | VLA2001 | IM | Valneva, National Institute for Health Research, United Kingdom | Phase 1/2 | NCT04671017 | ||||||
| 56 | PS | Protein subunit | BECOV2 | IM | Biological E. Limited | Phase 1/2 | CTRI/2020/11/029032 | ||||||
| 57 | VVr | Viral vector (Replicating) | AdCLD-CoV19 (adenovirus vector) | IM | Cellid Co., Ltd. | Phase 1/2 | NCT04666012 | ||||||
| 58 | DNA | DNA based vaccine | GLS-5310 | ID | GeneOne Life Science, Inc. | Phase 1/2 | NCT04673149 | ||||||
| 59 | PS | Protein subunit | Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted | IM | Nanogen Pharmaceutical Biotechnology | Phase 1/2 | NCT04683484 | ||||||
| 60 | PS | Protein subunit | Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) | IM | Shionogi | Phase 1/2 | jRCT2051200092 | ||||||
| Viral vector (Non-replicating) | AdCOVID, Adenovirus-based platform expresses the receptor-binding domain (RBD) of the Sars-Cov-2 spike protein | IN | Altimmune, Inc. | Phase 1 | NCT04679909 | ||||||||
| 61 | VVnr | Viral vector (Non-replicating) | AZD2816; adenoviral vector ChAdOx platform and based on the Beta (B.1.351) variant | IM | AstraZeneca + University of Oxford | Phase 2/3 | NCT04973449 | ||||||
| 62 | PS | Protein subunit | SARS-CoV-2-RBD-Fc fusion protein | SC or IM | University Medical Center Groningen + Akston Biosciences Inc. | Phase 1/2 | NCT04681092 | ||||||
| 63 | IV | Inactivated Virus | ERUCOV-VAC, inactivated virus | IM | Erciyes University | Phase 1 | NCT04691947 | ||||||
| 64 | PS | Protein subunit | COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant | IM | University of Saskatchewan | Phase 1/2 | NCT04702178 | ||||||
| 65 | PS | Protein subunit | GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide) |
IM | SK Bioscience Co., Ltd. | Phase 1/2 | NCT04742738 | ||||||
| NCT04750343 | |||||||||||||
| 66 | PS | Protein subunit | Razi Cov Pars, recombinant spike protein | IM and IN | Razi Vaccine and Serum Research Institute | Phase 1 | IRCT20201214049709N1 | ||||||
| 67 | IV | Inactivated Virus | COVID-19 inactivated vaccine | IM | Shifa Pharmed Industrial Co | Phase 1 | IRCT20201202049567N1 | ||||||
| 68 | PS | Protein subunit | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine | IM | The University of Queensland | Phase 1 | NCT04495933 | ||||||
| Study Report | |||||||||||||
| 69 | DNA | DNA based vaccine | COVIGEN | ID or IM | University of Sydney, Bionet Co., Ltd Technovalia |
Phase 1 | NCT04742842 |
||||||
| 70 | DNA | DNA based vaccine | COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein | IM | Takis + Rottapharm Biotech | Phase 1/2 | EudraCT:2020-003734-20 | ||||||
| 71 | VVnr | Viral vector (Non-replicating) | BBV154, Adenoviral vector COVID-19 vaccine | IN | Bharat Biotech International Limited | Phase 1 | NCT04751682 | ||||||
| 72 | DNA | DNA based vaccine | COVID-eVax, A plasmid DNA vaccine targeted Spike protein production | IM | Takis and Rottapharm Biotech | Phase 1/2 | EUCTR2020-003734-20-IT | ||||||
| 73 | RNA | RNA based vaccine | PTX-COVID19-B, mRNA vaccine | IM | Providence Therapeutics | Phase 1 | NCT04765436 | ||||||
| 74 | VVr | Viral vector (Replicating) | NDV-HXP-S, Newcastle disease virus (NDV) vector expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018 | IM | Mahidol University; The Government Pharmaceutical Organization (GPO); Icahn School of Medicine at Mount Sinai | Phase 1/2 | NCT04764422 | ||||||
| 75 | RNA | RNA based vaccine | CoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen | IM | GlaxoSmithKline | Phase 1 | NCT04758962 | ||||||
| 76 | VLP | Virus like particle | VBI-2902a. An enveloped virus-like particle (eVLP) of SARS-CoV-2 spike (S) glycoprotein and aluminum phosphate adjuvant. | IM | VBI Vaccines Inc. | Phase 1/2 | NCT04773665 | ||||||
| 77 | PS | Protein subunit | SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) + adjuvanted with alum. | IM | SK Bioscience Co., Ltd. | Phase 1 | NCT04760743 | ||||||
| 78 | VVnr | Viral vector (Non-replicating) | Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes. | IM | Gritstone Oncology | Phase 1 | NCT04776317 | ||||||
| 79 | RNA | RNA based vaccine | mRNA-1273.351. A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant. | IM | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | NCT04785144 | ||||||
| 80 | PS | Protein subunit | SpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant. | IM | Walter Reed Army Institute of Research (WRAIR) | Phase 1 | NCT04784767 | ||||||
| 81 | PS | Protein subunit | EuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant. | IM | EuBiologics Co.,Ltd | Phase 1/2 | NCT04783311 | ||||||
| 82 | LAV | Live attenuated virus | MV-014-212, a live attenuated vaccine that expresses the spike (S) protein of SARS-CoV-2 | IN | Meissa Vaccines, Inc. | Phase 1 | NCT04798001 | ||||||
| 83 | RNA | RNA based vaccine | MRT5500, an mRNA vaccine candidate | IM | Sanofi Pasteur and Translate Bio | Phase 1/2 | NCT04798027 | ||||||
| 84 | VLP | Virus like particle | SARS-CoV-2 VLP Vaccine | IM | The Scientific and Technological Research Council of Turkey | Phase 1 | NCT04818281 | ||||||
| 85 | PS | Protein subunit | ReCOV: Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell). | IM | Jiangsu Rec-Biotechnology | Phase 1 | NCT04818801 | ||||||
| 86 | RNA | RNA based vaccine | DS-5670a, mRNA vaccine | IM | Daiichi Sankyo Co., Ltd. | Phase 1/2 | NCT04821674 | ||||||
| 87 | IV | Inactivated Virus | Inactivated COVID-19 vaccine | IM | Kocak Farma | Phase 1 | NCT04838080 | ||||||
| 88 | VVnr | Viral vector (Non-replicating) | COVIVAC. Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein +/- adjuvant CpG 1018 | IM | Institute of Vaccines and Medical Biologicals Vietnam | Phase 1/2 | NCT04830800 | ||||||
| 89 | VVnr | Viral vector (Non-replicating) | SC-Ad6-1 Adneviral vector vaccine | IM | Tetherex Pharmaceuticals Corporation | Phase 1 | NCT04839042 | ||||||
| 90 | VLP | Virus like particle | ABNCoV2 capsid virus-like particle (cVLP) +/- adjuvant MF59 | IM | Radboud University | Phase 1 | NCT04839146 | ||||||
| 91 | PS | Protein subunit | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | IM | Guangdong Provincial Center for Disease Control and Prevention/Gaozhou Center for Disease Control and Prevention | Phase 2 | ChiCTR2100045108 | ChiCTR2100045107 | |||||
| 92 | RNA | RNA based vaccine | HDT-301: Self-replicating mRNA vaccine formulated as a lipid nanoparticle. | IM | SENAI CIMATEC | Phase 1 | NCT04844268 | ||||||
| 93 | IV | Inactivated Virus | Adjuvanted inactivated vaccine against SARS-CoV-2 | SC | The Scientific and Technological Research Council of Turkey (TÜBITAK) | Phase 1 | NCT04866069 | ||||||
| 94 | RNA | RNA based vaccine | mRNA-1283 | IM | ModernaTX, Inc. | Phase 1 | NCT04813796 | ||||||
| 95 | PS | Protein subunit | Recombinant SARS-CoV-2 Vaccine (CHO cell) | IM | National Vaccine and Serum Institute, China | Phase 1/2 | NCT04869592 | ||||||
| 96 | RNA | RNA based vaccine | EXG-5003; a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. | ID | Elixirgen Therapeutics, Inc | Phase 1/2 | NCT04863131 | ||||||
| 97 | IV | Inactivated Virus | Inactivated COVID-19 vaccine | IM | Elixirgen Therapeutics, IncKM Biologics Co., Ltd. | Phase 1/2 | jRCT2071200106 | ||||||
| 98 | IV | Inactivated Virus | Live recombinant Newcastle Disease Virus (rNDV) vector vaccine | IM or IN | Laboratorio Avi-Mex | Phase 1 | NCT04871737 | ||||||
| 99 | RNA | RNA based vaccine | mRNA COVID-19 vaccine | IM | Shanghai East Hospital and Stemirna Therapeutics | Phase 1 | |||||||
| 100 | PS | Protein subunit | CoVepiT vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural proteins) | SC | OSE Immunotherapeutics | Phase 1 | NCT04885361 | ||||||
| 101 | VVnr | Viral vector (Non-replicating) | Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein | IM | German Center for Infection Research | Phase 1/2 | NCT04895449 | ||||||
| 102 | PS | Protein subunit | CoV2-OGEN1, protein-based vaccine | Oral | VaxForm | Phase 1 | NCT04893512 | ||||||
| 103 | PS | Protein subunit | QazCoVac-P - COVID-19 Subunit Vaccine | IM | Research Institute for Biological Safety Problems | Phase 1/2 | NCT04930003 | ||||||
| 104 | RNA | RNA based vaccine | LNP-nCOV saRNA-02 vaccine; Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP) | IM | MRC/UVRI and LSHTM Uganda Research Unit | Phase 1 | NCT04934111 | ||||||
| 105 | RNA | RNA based vaccine | mRNA-1273.211. A multivalent booster candidate combining mRNA-1273 plus mRNA-1273.351. | IM | ModernaTX, Inc. | Phase 2/3 | NCT04927065 | ||||||
| 106 | PS | Protein subunit | RBD protein recombinant SARS-CoV-2 vaccine | IM | Bagheiat-allah University of Medical Sciences | Phase 1 | IRCT20210620051639N1 | ||||||
| 107 | PS | Protein subunit | Baiya SARS-CoV-2 VAX1, a plant-based subunit vaccine (RBD-Fc + adjuvant) | IM | Baiya Phytopharm Co., Ltd. | Phase 1 | NCT04953078 | ||||||
| 108 | PS | Protein subunit | SCB-2020S, an adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) | IM | Clover Biopharmaceuticals AUS Pty Ltd | Phase 2 | NCT04950751 ** | ||||||
| 109 | VVnr | Viral vector (Non-replicating) | PIV5 vector that encodes the SARS-CoV-2 spike protein | IM | CyanVac LLC | Phase 1 | NCT04954287 | ||||||
| 110 | PS | Protein subunit | 202-CoV; SARS-CoV-2 spike trimer protein + adjuvant, CpG7909. | IM | Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPI | Phase 1 | NCT04982068 | NCT04990544 | |||||
| 111 | DNA | DNA based vaccine | AG0302-COVID19 | IM | AnGes, Inc | Phase 1/2 | NCT04993586 | ||||||
| 112 | PS | Protein subunit | Recombinant protein RBD fusion dimer adjuvanted vaccine (COVID-19 Vaccine Hipra) | IM | Laboratorios Hipra, S.A. | Phase 1/2 | NCT05007509 | ||||||
| 113 | PS | Protein subunit | Versamune-CoV-2FC vaccine, recombinant S1 antigen | NR | Hospital do Coracao | Phase 1/2 | NCT05016934 | ||||||
| 114 | RNA | RNA based vaccine | ARCT-154 mRNA Vaccine | IM | Arcturus Therapeutics, Inc. | Phase 2/3 | NCT05037097 | NCT05012943 | |||||
| 115 | NA | PRNA based vaccine | ARCT-165 mRNA Vaccine | IM | Arcturus Therapeutics, Inc. | Phase 1/2 | NCT05037097 | ||||||
| 116 | NA | PRNA based vaccine | ARCT-021 mRNA Vaccine | IM | Arcturus Therapeutics, Inc. | Phase 1/2 | NCT05037097 | ||||||
| 117 | PS | Protein subunit | SII B.1.351 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.351 (Beta) variant vaccine | IM | Novavax | Phase 1/2 | NCT05029856 | ||||||
| 118 | PS | Protein subunit | SII Bivalent + Matrix-M1 adjuvant, a bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 | IM | Novavax | Phase 1/2 | NCT05029857 | ||||||
| 119 | PS | Protein subunit | SII B.1.617.2 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine | IM | Novavax | Phase 1/2 | NCT05029858 | ||||||
| 120 | VVnr | Viral vector (Non-replicating) | AAV5-RBD-S vaccine (BCD-250), A recombinant Adenovirus-Associated viral Vector (AAV-5) encoding spike protein | IM | Biocad | Phase 1/2 | NCT05037188 | ||||||
| 121 | PS | Protein subunit | SCTV01C. A Bivalent Recombinant Trimeric S Protein vaccine against SARS-CoV-2 Variants | IM | Sinocelltech Ltd. | Phase 2/3 | NCT05043311 | ||||||
| 122 | IV | Inactivated Virus | Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) | IM | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | Phase 1/2 | NCT05046548 | ||||||
| 123 | DNA | DNA based vaccine | Plasmid DNA vaccine SCOV1 + SCOV2. COVIDITY | ID/IM | Scancell Ltd | Phase 1 | NCT04982068 | ||||||
| 124 | BacAg-SpV | Bacterial antigen-spore expression vector | COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores | Oral | DreamTec Research Limited | NA | |||||||
| 125 | DNA | DNA based vaccine | VB10.2129, a DNA plasmid vaccine, encoding the receptor binding domain (RBD) | IM | Vaccibody AS | Phase 1/2 | NCT05069623 | ||||||
| 126 | DNA | DNA based vaccine | VB10.2210, DNA plasmid vaccine, encodes multiple immunogenic and conserved T cell epitopes spanning multiple antigens across the SARS-CoV-2 genome. | IM | Vaccibody AS | Phase 1/2 | NCT05069623 | ||||||
| 127 | ps | Protein subunit | SARS-CoV-2 Protein Subunit Recombinant Vaccine | IM | Bio Farma | Phase 1/2 | NCT05067894 | ||||||
| 128 | PS | Protein subunit | PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine | IM | Yisheng Biopharma | Phase 1 | ACTRN12621001009808 | ||||||
| 129 | DNA | DNA based vaccine | SARS-CoV-2 DNA vaccine (delivered IM followed by electroporation) | IM | The University of Hong Kong; Immuno Cure 3 Limited | Phase 1 | NCT05102643 | ||||||
| 131 | VVnr | Viral vector (Non-replicating) | Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins | AE | McMaster University | Phase 1 | NCT05094609 | ||||||
| 132 | PS | Protein subunit | PepGNP-SARSCoV2, A CD8 T-cell priming adaptive vaccine composed of a Coronaviruses specific peptides mounted on a gold nanoparticle | ID | Emergex Vaccines Holding Limited | Phase 1 | NCT05113862 | ||||||
| 133 | PS | Protein subunit | SARS-CoV-2 Vaccine (IN-B009) | IM | HK inno.N Corporation | Phase 1 | NCT05113849 | ||||||
| 134 | VLP | Virus like particle | SARS-CoV-2 Vaccine LYB001, a receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. | IM | Yantai Patronus Biotech Co., Ltd. | Phase 1 | NCT05125926 | NCT05137444 | |||||
| 135 | IV | Inactivated Virus | Covi Vax, inactivated coronavirus vaccine | IM | National Research Centre, Egypt | Phase 1 | NCT05128721 | ||||||
| 136 | RNA | RNA based vaccine | HDT-301 vaccine | IM | HDT Bio | Phase 1 | NCT05132907 | ||||||
| 137 | RNA | RNA based vaccine | VLPCOV-01, self-amplifying RNA vaccine against the coronavirus | IM | VLP Therapeutics Japan GK | Phase 1 | jRCT2071210067 | ||||||
194 candidate vaccines in preclinical evaluation
| ID | Vaccine platform acronym | Vaccine platform description | Type of candidate vaccine | Coronavirus target | Same platform for non-Coronavirus candidates | Developers |
| 1 | DNA | DNA based vaccine | DNA, engineered vaccine inserts compatible with multiple delivery systems | SARS-CoV-2 and Sarbeco-CoV | DIOSynVax Ltd + University of Cambridge | |
| 2 | DNA | DNA based vaccine | DNA vaccine | SARS-CoV2 | Ege University | |
| 3 | DNA | DNA based vaccine | DNA plasmid vaccine RBD&N | SARS-CoV2 | Scancell/University of Nottingham/ Nottingham Trent University | |
| 4 | DNA | DNA based vaccine | DNA with electroporation | SARS-CoV2 | Karolinska Institute / Cobra Biologics (OPENCORONA Project) | |
| 5 | DNA | DNA based vaccine | DNA with electroporation | SARS-CoV2 | Chula Vaccine Research Center | |
| 6 | DNA | DNA based vaccine | Plasmid DNA, Needle-Free Delivery | SARS-CoV2 | SARS | Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet |
| 7 | DNA | DNA based vaccine | DNA plasmid vaccine S,S1,S2,RBD &N | SARS-CoV2 | National Research Centre, Egypt | |
| 8 | DNA | DNA based vaccine | DNA vaccine | SARS-CoV2 | BioNet Asia | |
| 9 | DNA | DNA based vaccine | msDNA vaccine | SARS-CoV2 | Mediphage Bioceuticals/University of Waterloo | |
| 10 | DNA | DNA based vaccine | DNA vaccine | SARS-CoV2 | Entos Pharmaceuticals | |
| 11 | DNA | DNA based vaccine | DNA plasmids containing S-gene | SARS-CoV2 | Biosun Pharmed | |
| 12 | DNA | DNA based vaccine | DNA plasmid vaccine | SARS-CoV2 | Globe Biotech Limited, Bangladesh | |
| 13 | DNA | DNA based vaccine | Plasmid DNA, nanostructured RBD | SARS-CoV2 | National institute of Chemistry, Slovenia | |
| 14 | DNA | DNA based vaccine | DNA plasmid vaccine encoding RBD | SARS-CoV2 | Vaccibody, Oslo Research Park, Norway | |
| 15 | DNA | DNA based vaccine | DNA Immunostimulatory sequences | SARS-CoV2 | Inserm | |
| 16 | DNA | DNA based vaccine | The 3 regions of SARS-Cov-2 Spike-protein: NTD, RBD and HR1-HR2 inserted into the plasmid of PcDNA3.1 (+). | SARS-CoV2 | Center of Genomics and Bioinformatics of Academy of Science of Republic of Uzbekistan | |
| 17 | IV | Inactivated virus | Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 | SARS-CoV-2 | Institute Butantan (Brazil) / Dynavax / PATH | |
| 18 | IV | Inactivated virus | Inactivated + alum | SARS-CoV2 | JE, Zika | KM Biologics |
| 19 | IV | Inactivated virus | Inactivated | SARS-CoV2 | Selcuk University | |
| 20 | IV | Inactivated virus | SARS-CoV2 | Osaka University/ BIKEN/ NIBIOHN | ||
| 21 | IV | Inactivated virus | Inactivated + CpG 1018 | SARS-CoV2 | Sinovac/Dynavax | |
| 22 | IV | Inactivated virus | Inactivated + CpG 1018 | SARS-CoV2 | Valneva/Dynavax | |
| 23 | IV | Inactivated virus | Inactivated whole virus | SARS-CoV2 | National Research Centre, Egypt | |
| 24 | IV | Inactivated virus | Inactivated | SARS-CoV2 | MMR, IPV | Milad Pharmaceutics Co. |
| 25 | IV | Inactivated virus | Inactivated | SARS-CoV2 | MMR, IPV | Zista Kian Azma Co. |
| 26 | IV | Inactivated virus | Inactivated + alum | SARS-CoV2 | Paya Fan Yakhte Alborz - Osveh / Iran | |
| 27 | IV | Inactivated virus | Inactivated vaccine (Vero Cell) | SARS-CoV2 | Airlangga University, Indonesia in partnership with Biotis Pharmaceuticals Indonesia | |
| 28 | LAV | Live attenuated virus | Codon deoptimized live attenuated vaccines | SARS-CoV2 | Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S. | |
| 29 | LAV | Live attenuated virus | Codon deoptimized live attenuated vaccines | SARS-CoV2 | Indian Immunologicals Ltd/Griffith University | |
| 30 | LABV | Live attenuated bacterial vector | Live attenuated bacterial (Pertussis) Vector | SARS-CoV2 | Institut Pasteur Lille, Inserm | |
| 31 | LABV | Live attenuated bacterial vector | Live attenuated bacterial vector | SARS-CoV2 | ALtraBio, TheRex | |
| 32 | VVnr | Viral vector (Non-replicating) | Sendai virus vector | SARS-CoV2 | ID Pharma | |
| 33 | VVnr | Viral vector (Non-replicating) | Sendai virus vector | SARS-CoV2 | RSV, CMV | Max Planck Institute for Biochemstry/vir4vac, Germany |
| 34 | VVnr | Viral vector (Non-replicating) | Adenovirus-based | SARS-CoV2 | Ankara University | |
| 35 | VVnr | Viral vector (Non-replicating) | Adeno-associated virus vector (AAVCOVID) | SARS-CoV2 | Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis | |
| 36 | VVnr | Viral vector (Non-replicating) | MVA encoded VLP | SARS-CoV2 | LASV, EBOV, MARV, HIV | GeoVax/BravoVax |
| 37 | VVnr | Viral vector (Non-replicating) | MVA-S | SARS-CoV2 | IDIBAPS-Hospital Clinic, Spain | |
| 38 | VVnr | Viral vector (Non-replicating) | Adeno5-based | SARS-CoV2 | Erciyes University | |
| 39 | VVnr | Viral vector (Non-replicating) | Ad5 S (GREVAX™ platform) | SARS-CoV2 | MERS | Greffex |
| 40 | VVnr | Viral vector (Non-replicating) | Oral Ad5 S | SARS-CoV2 | Zika, VZV, HSV-2 and Norovirus | Stabilitech Biopharma Ltd |
| 41 | VVnr | Viral vector (Non-replicating) | Adenovirus-based + HLA-matched peptides | Pan-Corona | Valo Therapeutics Ltd | |
| 42 | VVnr | Viral vector (Non-replicating) | MVA expressing structural proteins | SARS-CoV2 | Multiple candidates | Centro Nacional Biotecnología (CNB-CSIC), Spain |
| 43 | VVnr | Viral vector (Non-replicating) | Parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein | SARS-CoV2 | MERS | University of Georgia/University of Iowa |
| 44 | VVnr | Viral vector (Non-replicating) | Recombinant deactivated rabies virus containing S1 | SARS-CoV2 | HeV, NiV, EBOV, LASSA, CCHFV, MERS | Bharat Biotech/Thomas Jefferson University |
| 45 | VVnr | Viral vector (Non-replicating) | Influenza A H1N1 vector | SARS-CoV2 | National Research Centre, Egypt | |
| 46 | VVnr | Viral vector (Non-replicating) | Newcastle disease virus expressing the spike protein | SARS-CoV2 | Icahn School of Medicine at Mount Sinai | |
| 47 | VVnr | Viral vector (Non-replicating) | Newcastle disease virus expressing membrane-anchored spike | SARS-CoV2 | Icahn School of Medicine at Mount Sinai | |
| 48 | VVnr | Viral vector (Non-replicating) | Lentiviral Vector | SARS-CoV2 | Theravectys – Institut Pasteur | |
| 49 | VVnr | Viral vector (Non-replicating) | Lentiviral Vector | SARS-CoV2 | AIOVA | |
| 50 | VVnr | Viral vector (Non-replicating) | Lentiviral Vector Retro-VLP Particles | SARS-CoV2 | Sorbonne University | |
| 51 | VVnr | Viral vector (Non-replicating) | Ad 5 vector for intranasal administration | SARS-CoV2 | University of Helsinki & University of Eastern Finland | |
| 52 | VVnr | Viral vector (Non-replicating) | Oral vaccine platform | SARS-CoV2 | InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE | Vaxart |
| 53 | VVnr | Viral vector (Non-replicating) | Recombinant Adenovirus Vector (Type 5) + Spike protein of SARS-CoV-2 | SARS-CoV2 | Pasteur Institute / Iran | |
| 54 | VVnr | Viral vector (Non-replicating) | Recombinant Adenovirus Vector (ChAdOx1) + Spike protein of SARS-CoV-2 | SARS-CoV2 | Pasteur Institute / Iran | |
| 55 | VVnr | Viral vector (Non-replicating) | Adenovirus-based | SARS-CoV2 | Home Iman Zist Fanavar | |
| 56 | VVnr | Viral vector (Non-replicating) | Chimpanzee adenovirus vector expressing the RBD-dimer without adjuvant | SARS-CoV2 | Chengdu Kanghua Biological Products Co., Ltd. | |
| 57 | PS | Protein subunit | RBD protein delivered in mannose-conjugated chitosan nanoparticle | SARS-CoV2 | Ohio State University / Kazakh National Agrarian University | |
| 58 | PS | Protein subunit | Recombinant spike protein with Essai O/W 1849101 adjuvant | SARS-CoV2 | Kazakh National Agrarian University | |
| 59 | PS | Protein subunit | Peptides | SARS-CoV2 | Neo7Logic | |
| 60 | PS | Protein subunit | Recombinant spike protein with Essai O/W 1849101 adjuvant | SARS-CoV2 | Kazakh National Agrarian University, Kazakhstan / National Scientific Center for Especially Dangerous Infections | |
| 61 | PS | Protein subunit | Recombinant S protein | SARS-CoV2 | Max-Planck-Institute of Colloids and Interfaces | |
| 62 | PS | Protein subunit | RBD protein (baculovirus production) + FAR-Squalene adjuvant | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH) |
| 63 | PS | Protein subunit | RBD-protein | SARS-CoV2 | Mynvax | |
| 64 | PS | Protein subunit | Recombinant S protein | SARS-CoV2 | Izmir Biomedicine and Genome Center | |
| 65 | PS | Protein subunit | Peptide + novel adjuvant | SARS-CoV2 | Bogazici University | |
| 66 | PS | Protein subunit | S subunit intranasal liposomal formulation with GLA/3M052 adjs. | SARS-CoV2 | University of Virginia | |
| 67 | PS | Protein subunit | S-Protein (Subunit) + Adjuvant, E coli and Insect vectors for expression/synthesis of the protein | SARS-CoV2 | Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria. | |
| 68 | PS | Protein subunit | Protein Subunit S,N,M&S1 protein | SARS-CoV2 | National Research Centre, Egypt | |
| 69 | PS | Protein subunit | Protein Subunit | SARS-CoV2 | University of San Martin and CONICET, Argentina | |
| 70 | PS | Protein subunit | RBD protein fused with Fc of IgG + Adj. | SARS-CoV2 | Chulalongkorn University/GPO, Thailand | |
| 71 | PS | Protein subunit | Capsid-like Particle | SARS-CoV2 | AdaptVac (PREVENT-nCoV consortium) | |
| 72 | PS | Protein subunit | Drosophila S2 insect cell expression system VLPs | SARS-CoV2 | ExpreS2ion | |
| 73 | PS | Protein subunit | Peptide antigens formulated in LNP | SARS-CoV2 | IMV Inc | |
| 74 | PS | Protein subunit | S protein | SARS-CoV2 | WRAIR/USAMRIID | |
| 75 | PS | Protein subunit | S protein +Adjuvant | SARS-CoV2 | Influenza | National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma |
| 76 | PS | Protein subunit | VLP-recombinant protein + Adjuvant | SARS-CoV2 | Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan | |
| 77 | PS | Protein subunit | microneedle arrays S1 subunit | SARS-CoV2 | MERS | Univ. of Pittsburgh |
| 78 | PS | Protein subunit | Peptide | SARS-CoV2 | Vaxil Bio | |
| 79 | PS | Protein subunit | Adjuvanted protein subunit (RBD) | SARS-CoV2 | Biological E Ltd | |
| 80 | PS | Protein subunit | Peptide | SARS-CoV2 | Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine | Flow Pharma Inc |
| 81 | PS | Protein subunit | S protein | SARS-CoV2 | AJ Vaccines | |
| 82 | PS | Protein subunit | Ii-Key peptide | SARS-CoV2 | Influenza, HIV, SARS-CoV | Generex/EpiVax |
| 83 | PS | Protein subunit | S protein | SARS-CoV2 | H7N9 | EpiVax/Univ. of Georgia |
| 84 | PS | Protein subunit | Protein Subunit EPV-CoV-19 | SARS-CoV2 | EpiVax | |
| 85 | PS | Protein subunit | gp-96 backbone | SARS-CoV2 | NSCLC, HIV, Malaria, Zika | Heat Biologics/Univ. Of Miami |
| 86 | PS | Protein subunit | Subunit vaccine | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 87 | PS | Protein subunit | S1 or RBD protein | SARS-CoV2 | SARS | Baylor College of Medicine |
| 88 | PS | Protein subunit | Subunit protein, plant produced | SARS-CoV2 | iBio/CC-Pharming | |
| 89 | PS | Protein subunit | Recombinant protein, nanoparticles (based on S-protein and other epitopes) | SARS-CoV2 | Saint-Petersburg scientific research institute of vaccines and serums | |
| 90 | PS | Protein subunit | Cross-reactive T-cell recombinant vaccine based on SARS-CoV-2 nucleoprotein (N) expressed in E.coli | SARS-CoV2 | various (cross-immunity) | FSUE SPbSRIVS FMBA of Russia (St. Petersburg Institute of Vaccines) |
| 91 | PS | Protein subunit | COVID-19 XWG-03 truncated S (spike) proteins | SARS-CoV2 | HPV | Innovax/Xiamen Univ./GSK |
| 92 | PS | Protein subunit | Adjuvanted microsphere peptide | SARS-CoV2 | VIDO-InterVac, University of Saskatchewan | |
| 93 | PS | Protein subunit | Synthetic Long Peptide Vaccine candidate for S and M proteins | SARS-CoV2 | OncoGen | |
| 94 | PS | Protein subunit | Oral E. coli-based protein expression system of S and N proteins | SARS-CoV2 | MIGAL Galilee Research Institute | |
| 95 | PS | Protein subunit | Nanoparticle vaccine | SARS-CoV2 | LakePharma, Inc. | |
| 96 | PS | Protein subunit | Plant-based subunit (RBD-Fc + Adjuvant) | SARS-CoV2 | Baiya Phytopharm/ Chula Vaccine Research Center | |
| 97 | PS | Protein subunit | OMV-based vaccine | SARS-CoV2 | Flu A, Plague | Quadram Institute Biosciences |
| 98 | PS | Protein subunit | OMV-based vaccine | SARS-CoV2 | BiOMViS Srl/Univ. of Trento | |
| 99 | PS | Protein subunit | structurally modified spherical particles of the tobacco mosaic virus (TMV) | SARS-CoV2 | Rubella, Rotavirus | Lomonosov Moscow State University |
| 100 | PS | Protein subunit | Spike-based | SARS-CoV2 | Hepatitis C | University of Alberta |
| 101 | PS | Protein subunit | Recombinant S1-Fc fusion protein | SARS-CoV2 | AnyGo Technology | |
| 102 | PS | Protein subunit | Recombinant protein | SARS-CoV2 | Yisheng Biopharma | |
| 103 | PS | Protein subunit | Recombinant S protein in IC-BEVS (Viral vector vaccine (based on baculovirus expression system in insect cell line) |
SARS-CoV2 | Vabiotech, Vietnam and University of Bristol, UK | |
| 104 | PS | Protein subunit | Orally delivered, heat stable subunit | SARS-CoV2 | Applied Biotechnology Institute, Inc. | |
| 105 | PS | Protein subunit | Peptides derived from Spike protein | SARS-CoV2 | Axon Neuroscience SE | |
| 106 | PS | Protein subunit | Protein Subunit | SARS-CoV2 | MOGAM Institute for Biomedical Research, GC Pharma | |
| 107 | PS | Protein subunit | RBD-based | SARS-CoV2 | Neovii/Tel Aviv University | |
| 108 | PS | Protein subunit | Outer Membrane Vesicle (OMV)-subunit | SARS-CoV2 | Intravacc/Epivax | |
| 109 | PS | Protein subunit | Spike-based (epitope screening) | SARS-CoV2 | ImmunoPrecise/LiteVax BV | |
| 110 | PS | Protein subunit | Spiked-based | SARS-CoV2 | Nanografi Nano Technology, Middle East Technical University, Ankara University, | |
| 111 | PS | Protein subunit | Recombinant spike with adjuvant | SARS-CoV2 | Iran | |
| 112 | PS | Protein subunit | Recombinant S protein produced in BEVS | SARS-CoV2 | Tampere University | |
| 113 | PS | Protein subunit | Protein Subunit Nanoformulated | SARS-CoV2 | Vaxinano, CEA, INRAE | |
| 114 | PS | Protein subunit | Protein Subunit Adenoviral Carrier | SARS-CoV2 | CEA, CNRS | |
| 115 | PS | Protein subunit | Protein DC-targeted epitopes | SARS-CoV2 | LinkinVax, VRI, Inserm | |
| 116 | PS | Protein subunit | Soluble recombinant S protein produced in CHO cells | SARS-CoV2 | Center for Advanced Technologies, Uzbekistan | |
| 117 | PS | Protein subunit | NYVAC-KC, attenuated vaccinia virus vector expressing SARS-CoV-2 Spike and other viral proteins | SARS-CoV2 | Arizona State University | |
| 118 | PS | Protein subunit | Protein peptides with alum | SARS-CoV2 | Hacettepe University, Turkey | |
| 119 | PS | Protein subunit | Recombinant Spike (S) proteins encoded by Baculoviruses in Insect cells | SARS-CoV2 | Marmara University, Turkey | |
| 120 | PS | Protein subunit | Adjuvanted Peptides + Recombinant Spike Protein | SARS-CoV2 | Yıldız Technical University, Turkey | |
| 121 | PS | Protein subunit | Development of recombinant protein based S1 and S2 (Spike) and nucleocapsid subunits vaccines using a plant expression vector. | SARS-CoV2 | Akdeniz University, Department of Agricultural Biotechnology, Antalya, Turkey | |
| 122 | PS | Protein subunit | Recombinant Protein Vaccine | SARS-CoV2 | Ataturk University, Vaccine Research Center (Erzurum) and Health Institutes of Turkey (TUSEB) | |
| 123 | PS | Protein subunit | Recombinant protein subunit vaccine | SARS-CoV2 | Pharmada Pharmaceuticals/TURKEY | |
| 124 | PS | Protein subunit | Recombinant Spike Protein | SARS-CoV2 | CinnaGen Co | |
| 125 | PS | Protein subunit | Recombinant SARS CoV-2 RBD Protein, Alum adjuvanted | SARS-CoV2 | Bio Farma + Baylor College Medicine | |
| 126 | PS | Protein subunit | TerraCoV2 recombinant protein (stabilized pre-fusion spike protein) | Wuhan B.1.351 (Beta) | Oragenics Inc, in cooperation with NRC Canada and Biodextris, Inc | |
| 127 | PS | Protein subunit | Multiple peptides fragments targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins to induce T cell responses (CD8) | SARS-CoV2 | OSE immunotherapeutics | |
| 128 | PS | Protein subunit | BD-COV-001 B.1.351 antigen encapsulated in polymersomes | SARS-CoV2 | ACM Biosciences | |
| 129 | PS | Protein subunit | Recombinant protein | SARS-CoV2 | Biosun Pharmed / Iran | |
| 130 | PS | Protein subunit | Recombinant protein with hepatitis B VLP vector + Alum | SARS-CoV3 | Rahpouyan Fanavar Sadegh (RFS) / Iran | |
| 131 | PS | Protein subunit | Recombinant Protein (Leishmania host) | SARS-CoV4 | Zist Salak / Iran | |
| 132 | BVr | Bacterial vector (Replicating) | Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) |
| 133 | VVr | Viral vector (Replicating) | YF17D Vector | SARS-CoV2 | KU Leuven | |
| 134 | VVr | Viral vector (Replicating) | Measles Vector | SARS-CoV2 | Cadila Healthcare Limited | |
| 135 | VVr | Viral vector (Replicating) | Measles Vector | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 136 | VVr | Viral vector (Replicating) | Measles Virus (S, N targets) | SARS-CoV2 | Zika, H7N9, CHIKV | DZIF – German Center for Infection Research/CanVirex AG |
| 137 | VVr | Viral vector (Replicating) | Horsepox vector expressing S protein | SARS-CoV2 | Smallpox, Monkeypox | Tonix Pharma/Southern Research |
| 138 | VVr | Viral vector (Replicating) | Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) | SARS-CoV2 | Influenza | BiOCAD and IEM |
| 139 | VVr | Viral vector (Replicating) | Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal) | SARS-CoV2 | Influenza | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo |
| 140 | VVr | Viral vector (Replicating) | Attenuated Influenza expressing an antigenic portion of the Spike protein | SARS-CoV2 | Influenza | Fundação Oswaldo Cruz and Instituto Buntantan |
| 141 | VVr | Viral vector (Replicating) | Influenza vector expressing RBD | SARS-CoV2 | University of Hong Kong | |
| 142 | VVr | Viral vector (Replicating) | Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein. | SARS-CoV2 | Ebola, Marburg, Lassa | IAVI/Merck |
| 143 | VVr | Viral vector (Replicating) | Replicating VSV vector-based DC-targeting | SARS-CoV2 | University of Manitoba | |
| 144 | VVr | Viral vector (Replicating) | VSV-S | SARS-CoV2 | HIV, MERS | University of Western Ontario |
| 145 | VVr | Viral vector (Replicating) | VSV-S | SARS-CoV2 | Aurobindo | |
| 146 | VVr | Viral vector (Replicating) | VSV vector | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 147 | VVr | Viral vector (Replicating) | M2-deficient single replication (M2SR) influenza vector | SARS-CoV2 | Influenza | UW–Madison/FluGen/Bharat Biotech |
| 148 | VVr | Viral vector (Replicating) | Newcastle disease virus vector (NDV-SARS-CoV-2/Spike) | SARS-CoV2 | Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ. | |
| 149 | VVr | Viral vector (Replicating) | Avian paramyxovirus vector (APMV) | SARS-CoV2 | The Lancaster University, UK | |
| 150 | VVr | Viral vector (Replicating) | Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing RBD protein: rNDV-LS1-HN-RBD/SARS-CoV-2 | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) |
| 151 | VVr | Viral vector (Replicating) | Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing S1 protein: rNDV-LS1-S1-F/SARS-CoV-2 | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) |
| 152 | RNA | RNA based vaccine | saRNA formulated in a NLC | SARS-CoV2 | Infectious Disease Research Institute/ Amyris, Inc. | |
| 153 | RNA | RNA based vaccine | LNP-encapsulated mRNA encoding S | SARS-CoV2 | Max-Planck-Institute of Colloids and Interfaces | |
| 154 | RNA | RNA based vaccine | Self-amplifying RNA | SARS-CoV2 | Gennova | |
| 155 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Selcuk University | |
| 156 | RNA | RNA based vaccine | LNP-mRNA | SARS-CoV2 | Translate Bio/Sanofi Pasteur | |
| 157 | RNA | RNA based vaccine | LNP-mRNA | SARS-CoV2 | CanSino Biologics/Precision NanoSystems | |
| 158 | RNA | RNA based vaccine | LNP-encapsulated mRNA cocktail encoding VLP | SARS-CoV2 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | |
| 159 | RNA | RNA based vaccine | LNP-encapsulated mRNA encoding RBD | SARS-CoV2 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | |
| 160 | RNA | RNA based vaccine | Replicating Defective SARS-CoV-2 derived RNAs | SARS-CoV2 | Centro Nacional Biotecnología (CNB-CSIC), Spain | |
| 161 | RNA | RNA based vaccine | LNP-encapsulated mRNA | SARS-CoV2 | MERS | University of Tokyo/ Daiichi-Sankyo |
| 162 | RNA | RNA based vaccine | Liposome-encapsulated mRNA | SARS-CoV2 | BIOCAD | |
| 163 | RNA | RNA based vaccine | Several mRNA candidates | SARS-CoV2 | RNAimmune, Inc. | |
| 164 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 165 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | China CDC/Tongji University/Stermina | |
| 166 | RNA | RNA based vaccine | mRNA in an intranasal delivery system | SARS-CoV2 | eTheRNA | |
| 167 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Greenlight Biosciences | |
| 168 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | IDIBAPS-Hospital Clinic, Spain | |
| 169 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Providence Therapeutics | |
| 170 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Cell Tech Pharmed | |
| 171 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | ReNAP Co. | |
| 172 | RNA | RNA based vaccine | D614G variant LNP-encapsulated mRNA | SARS-CoV2 | Globe Biotech Ltd | |
| 173 | RNA | RNA based vaccine | Encapsulated mRNA | SARS-CoV2 | CEA | |
| 174 | RNA | RNA based vaccine | Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen | SARS-CoV2 | Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX) | |
| 175 | RNA | RNA based vaccine | ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes for multiple antigens, including the Spike (S) protein. | SARS-CoV2 | Ziphius Vaccines and Ghent University | |
| 176 | VLP | Virus like particle | VLP | SARS-CoV2 | Max Planck Institute for Dynamics of Complex Technical Systems | |
| 177 | VLP | Virus like particle | Virus-like particle-based Dendritic Cell(DC)-targeting vaccine | SARS-CoV2 | University of Manitoba | |
| 178 | VLP | Virus like particle | VLP | SARS-CoV2 | Bezmialem Vakif University | |
| 179 | VLP | Virus like particle | Enveloped Virus-Like Particle (eVLP) | SARS-CoV-2, SARS-CoV, & MERS-CoV | CMV, GBM, Zika | VBI Vaccines Inc. |
| 180 | VLP | Virus like particle | S protein integrated in HIV VLPs | SARS-CoV2 | IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols | |
| 181 | VLP | Virus like particle | VLP + Adjuvant | SARS-CoV2 | Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital | |
| 182 | VLP | Virus like particle | Virus-like particles, lentivirus and baculovirus vehicles | SARS-CoV2 | Navarrabiomed, Oncoimmunology group | |
| 183 | VLP | Virus like particle | Virus-like particle, based on RBD displayed on virus-like particles | SARS-CoV2 | Saiba GmbH | |
| 184 | VLP | Virus like particle | ADDomerTM multiepitope display | SARS-CoV2 | Imophoron Ltd and Bristol University’s Max Planck Centre | |
| 185 | VLP | Virus like particle | Unknown | SARS-CoV2 | Doherty Institute | |
| 186 | VLP | Virus like particle | VLP | SARS-CoV1, SARS-CoV2 | OSIVAX | |
| 187 | VLP | Virus like particle | eVLP | SARS-CoV2 | Malaria | ARTES Biotechnology |
| 188 | VLP | Virus like particle | VLPs peptides/whole virus | SARS-CoV2 | Univ. of Sao Paulo | |
| 189 | VLP | Virus like particle | VLPs produced in BEVS | SARS-CoV2 | Tampere University | |
| 190 | VLP | Virus like particle | Plant derived VLP | SARS-CoV2 | Shiraz University | |
| 191 | VLP | Virus like particle | Myxoma virus co-expressing S, M, N and E proteins | SARS-CoV2 | Arizona State University | |
| 192 | VLP | Virus like particle | Plasmid driven production of virus -Like-Particles (VLPs) containing S, M, N and E proteins of SARS-CoV-2 | SARS-CoV2 | Arizona State University | |
| 193 | VLP | Virus like particle | Virus Like Particle with RCB | SARS-CoV2 | Berna Biotech Pharma | |
| 194 | Cell | Cellular based vaccine | Engineered human mesenchymal stem cells transfected with a plasmid expressing S and N-protein | SARS-CoV2 | Cell Tech Pharmed |
Facebook
LinkedIn
Twitter
